Compound Library

25 compounds published so far -- half-lives, dosing forms, discovery history, and what the research actually found. Every finding carries its evidence tier and how far that study sits from real-world use, so a randomized trial of a different molecule never reads as proof about this one.

Injectable AAS

Sustanon 250 (blend avg)

Injectable AAS

Blend of 4 testosterone esters (propionate 30mg, phenylpropionate 60mg, isocaproate 60mg, decanoate 100mg). Designed for less frequent injections but levels can be unstable.

half-life 4.5 d1 rct - 5 clinical - 2 anecdotal

Testosterone Cypionate

Injectable AAS

Very similar to enanthate with slightly longer half-life. Most common TRT ester in the US. Near-identical PK profile to enanthate.

half-life 6.9 d1 rct - 5 clinical - 1 anecdotal

Testosterone Enanthate

Injectable AAS

Most commonly used testosterone ester. Good balance of injection frequency and stable levels. Standard for TRT and cycles.

half-life 7.19 d2 rct - 5 clinical - 1 anecdotal

Testosterone Propionate

Injectable AAS

Short-acting testosterone ester. Fast peak within hours, requires frequent injections (EOD or daily) for stable levels. Often used at cycle start for quick onset.

half-life 1.04 d5 clinical - 1 preclinical - 2 anecdotal

Peptide Hormone

HCG

Peptide Hormone

Human Chorionic Gonadotropin. LH analog that stimulates testicular testosterone production. Used during cycles to prevent testicular atrophy and during PCT.

half-life 1.96 d2 rct - 5 clinical - 1 anecdotal

HGH (Somatropin)

Peptide Hormone

Recombinant human Growth Hormone. Used for body composition, recovery, and anti-aging. Pulsatile release pattern, best injected SubQ.

half-life 0.17 d5 rct - 1 clinical - 1 preclinical - 1 anecdotal

Peptide

BPC-157*

Peptide

Body Protection Compound-157. Pentadecapeptide with gastric protective and wound healing properties in animal studies. Not FDA-approved. Mechanism involves VEGF, NO, and growth factor modulation.

half-life 0.17 d1 rct - 2 clinical - 4 preclinical - 1 anecdotal

GHK-Cu*

Peptide

Copper-binding tripeptide (glycyl-L-histidyl-L-lysine). Naturally occurring in plasma. Promotes collagen synthesis, wound healing, and has anti-inflammatory properties.

half-life 0.063 d3 rct - 4 preclinical - 1 anecdotal

Melanotan II*

Peptide

Non-selective melanocortin receptor agonist. Promotes tanning and can cause nausea. Not FDA-approved. Limited Phase I data available.

half-life 0.042 d5 clinical - 1 preclinical - 1 anecdotal

PT-141 (Bremelanotide)

Peptide

MC4R agonist. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Full human PK characterization available.

half-life 0.11 d2 rct - 4 clinical - 1 preclinical - 1 anecdotal

TB-500 / TB4*

Peptide

Synthetic fragment of Thymosin Beta-4. Promotes wound healing, tissue repair, and reduced inflammation in animal studies. Used in equine and veterinary medicine.

half-life 0.1 d2 rct - 1 clinical - 4 preclinical - 1 anecdotal

GHRH Analog

CJC-1295 No DAC

GHRH Analog

Modified GRF (1-29). Short-acting GHRH analog for pulsatile GH release. Best used with a GHRP (like ipamorelin) for synergistic effect.

half-life 0.021 d1 rct - 4 clinical - 1 preclinical - 2 anecdotal

Sermorelin

GHRH Analog

Synthetic 29-amino-acid analog of GHRH. FDA-approved for pediatric GH deficiency; used off-label for adult GH support.

half-life 0.007 d1 rct - 3 clinical - 2 preclinical - 1 anecdotal

Tesamorelin

GHRH Analog

Stabilized analog of GHRH(1-44). FDA-approved as Egrifta for HIV-associated lipodystrophy.

half-life 0.018 d6 rct - 1 preclinical - 1 anecdotal

GHRP

Ipamorelin

GHRP

Selective GH secretagogue with minimal effect on cortisol and prolactin. Often combined with CJC-1295 No DAC for synergistic GH pulse.

half-life 0.083 d1 rct - 3 clinical - 3 preclinical - 1 anecdotal

GLP-1 Agonist

Liraglutide

GLP-1 Agonist

FDA-approved GLP-1 receptor agonist for T2DM (Victoza) and obesity (Saxenda). Daily SubQ; ~8% weight loss at 3mg in SCALE.

half-life 0.54 d4 rct - 1 preclinical - 1 anecdotal

Semaglutide

GLP-1 Agonist

FDA-approved lipidated GLP-1 receptor agonist (Ozempic/Wegovy). Long half-life allows weekly dosing. Used for T2DM and obesity.

half-life 6.5 d5 rct - 1 preclinical - 1 anecdotal

GLP-1/GIP Agonist

Tirzepatide

GLP-1/GIP Agonist

FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro). Shows greater weight loss efficacy than semaglutide in head-to-head trials.

half-life 4.86 d5 rct - 1 anecdotal

GLP-1/GIP/GCG Agonist

Retatrutide

GLP-1/GIP/GCG Agonist

Triple-acting incretin receptor agonist from Eli Lilly. Phase 2 showed up to 24% body weight loss at 48 weeks. Weekly SubQ injection.

half-life 6.14 d5 rct - 1 clinical - 1 preclinical - 1 anecdotal

Mitochondrial Peptide

Mots-c*

Mitochondrial Peptide

Mitochondrial-derived peptide encoded by mtDNA. Pre-clinical data suggests insulin-sensitizing and metabolic regulation effects.

half-life 0.5 d4 clinical - 3 preclinical - 1 anecdotal

GH Secretagogue

MK-677 (Ibutamoren)

GH Secretagogue

Oral non-peptide ghrelin receptor agonist. Long half-life allows once-daily dosing. Increases GH and IGF-1 levels.

half-life 1 d7 rct - 1 anecdotal

Metabolic

NAD+*

Metabolic

Nicotinamide adenine dinucleotide. Coenzyme; precursors include NR and NMN. IV administration most common clinically.

half-life 0.003 d3 rct - 3 clinical - 1 preclinical - 1 anecdotal

AI

Anastrozole

AI

Non-steroidal aromatase inhibitor. FDA-approved as Arimidex for breast cancer; used off-label to control estrogen during cycles.

half-life 1.95 d6 rct - 1 clinical - 1 anecdotal

SERM

Enclomiphene

SERM

trans-isomer of clomiphene. Phase II trials suggest cleaner side-effect profile than mixed-isomer Clomid.

half-life 0.42 d4 rct - 2 clinical - 1 preclinical - 1 anecdotal

Amylin Analog

Cagrilintide

Amylin Analog

Phase 3 long-acting amylin analog (Novo Nordisk); complements GLP-1s via the amylin/CGRP receptor. CagriSema (cagrilintide+semaglutide 2.4mg) reached ~22.7% weight loss at 68wk. PK estimated.

half-life 7.5 d4 rct - 1 clinical - 1 preclinical - 1 anecdotal

Not medical advice. DosePlot is an informational tool, not a healthcare provider, and using it creates no provider-patient relationship. Do not start, stop, or change any protocol without the approval of a licensed healthcare professional.

Your whole protocol, in one place.

Free to start. Runs in your browser today.

14-day Premium trial inside, no card required.

Launch the web app